Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus

Phase 2 Completed 27 enrolled Pharma Holdings AS CTC Clinical Trial Consultants AB · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

A Phase IIa, double-blind, placebo-controlled, randomised study designed to evaluate the efficacy, safety and tolerability of two dosing regimens with LTX-109 administered topically to the anterior nares in subjects with persistent carriage of Staphylococcus aureus (S. aureus).

Timeline

Start: 2022-09-19
Primary completion: 2022-10-28
Completion: 2022-10-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	LTX-109	Peptide	3 %	Topical

Indications

No indication recorded.